2. Search Result
Search Result
Results for "

mutant strains

" in MedChemExpress (MCE) Product Catalog:

57

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dyes

1

Biochemical Assay Reagents

1

Peptides

4

Natural
Products

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17040
    Darunavir
    Maximum Cited Publications
    17 Publications Verification

    TMC114; UIC-94017

    		 HIV HIV Protease Infection Inflammation/Immunology
    Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity .
    Darunavir
  • HY-131033
    L-Azidonorleucine hydrochloride

    		Biochemical Assay Reagents Others
    L-Azidonorleucine hydrochloride, an unnatural amino acid, is A Methionine surrogate. L-Azidonorleucine hydrochloride can be used to label mammalian cell proteins and identify a diverse set of methionyl-tRNA synthetase (MetRS) mutants . L-Azidonorleucine (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    L-Azidonorleucine hydrochloride
  • HY-109142
    Ziresovir
    5 Publications Verification

    AK0529; RO-0529

    		 RSV Infection
    Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species .
    Ziresovir
  • HY-135498
    Ferrioxamine E

    		Bacterial Infection
    Ferrioxamine E is a siderophore and bacterial growth regulator. Ferrioxamine E can chelate ferric iron, and promote the growth, morphological differentiation and antibiotic synthesis of Streptomyces tanashiensis .
    Ferrioxamine E
  • HY-D1056C5
    Lipopolysaccharides, from S. enterica serotype minnesota Re 595 (Re mutant)

    LPS, from Salmonella enterica (Serotype minnesota Re 595 (Re mutant))

    		 Toll-like Receptor (TLR) Bacterial Inflammation/Immunology
    Lipopolysaccharides (LPS), from S. enterica (Salmonella enterica) serotype minnesota Re 595 (Re mutant) is prepared from Salmonella enterica strain Re 595 (Re mutant). The structure in the LPS of strain Re 595 was shown to induce secretion and aggregation in human platelets .
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from S. enterica serotype minnesota Re 595 (Re mutant)
  • HY-157403
    Jun12682
    1 Publications Verification

    		 Virus Protease SARS-CoV Infection
    Jun12682 is an orally active SARS-CoV-2 papain-like protease (PL pro) inhibitor, with a Ki value of 37.7 nM and an EC50 value of 1.1 μM in the FlipGFP PL pro assay. Jun12682 has efficacy in hindering PL pro both deubiquitination and deISGylation, with Ki values of 63.5 and 38.5 nM, respectively. Jun12682 exhibits resistance in multiple PL pro mutant strains, and its enzymatic activity is comparable to that of the wild-type. Jun12682 can be used for the study of the SARS-CoV-2 .
    Jun12682
  • HY-N3920
    Gancaonin G

    		Bacterial Infection
    Gancaonin G is a 6-prenylated isoflavanone that can be isolated from Glycyrrhiza uralensis. Gancaonin G has antibacterial activity against Streptococcus mutants and MRSA strains .
    Gancaonin G
  • HY-146145
    Metyltetraprole

    		Fungal Mitochondrial Metabolism Infection
    Metyltetraprole is a promising fungicide with EC50 values of both 0.002 ppm against sensitive wild-type and G143A mutant of Zymoseptoria tritici. Metyltetraprole is effective against QoI (quinone outside inhibitor) resistant strains. Metyltetraprole inhibits the respiratory chain via complex III .
    Metyltetraprole
  • HY-152161
    HIV-1 inhibitor-51

    		HIV Reverse Transcriptase Infection
    HIV-1 inhibitor-51, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exhibits outstanding antiviral activity against WT HIV-1 (IIIB) and a panel of mutant strains. HIV-1 inhibitor-51 has high binding affinity (KD=2.50 μM) and inhibitory activity (IC50=0.03 μM) to WT HIV-1 RT. HIV-1 inhibitor-51 has EC50s of 2.22-53.3 nM for mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L + V106A, RES056) .
    HIV-1 inhibitor-51
  • HY-152160
    HIV-1 inhibitor-50

    		HIV Reverse Transcriptase Infection
    HIV-1 invistor-50 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets HIV-1 reverse transcriptase (RT) (IC50=50 nM). HIV-1 inhibitor-50 shows significant antiviral activity, with EC50s of 2.22-53.3nM against HIV-1 IIIB and its mutant strains .
    HIV-1 inhibitor-50
  • HY-15352
    BMS 561390

    DPC 083

    		 Reverse Transcriptase HIV Infection
    BMS 561390 (DPC 083) is an orally available non-nucleoside reverse transcriptase inhibitor (NNRTI) with broad inhibitory effects on wild-type HIV-1 and mutant strains .
    BMS 561390
  • HY-175351
    HIV-1-IN-83

    		HIV Reverse Transcriptase Infection
    HIV-1-IN-83 (Compound 18E) is a HIV-1 non-nucleoside reverse transcriptase inhibitor with an IC50 of 0.45 μM for wild-type HIV-1 non-nucleoside reverse transcriptase. HIV-1-IN-83 has potent antiviral activity against both HIV-1 wild-type and mutant strains and improves antidrug resistance for Y188L and RES056 mutant strains. HIV-1-IN-83 has no significant toxicity up to 11.088 μM .
    HIV-1-IN-83
  • HY-P1974
    FR 901379

    WF11899A

    		 Antibiotic Infection
    FR901379 (WF11899A) is a novel echinocandin-type lipopeptide antibiotic. FR901379 is primarily produced by mutant strain M-7 of Coleophoma empetri F-11899 (FERM BP-2635) .
    FR 901379
  • HY-129943
    Benzothiohydrazide

    		Bacterial Infection
    Benzothiohydrazide is an analogue of anti–tubercular agent Isoniazid. Benzothiohydrazide exhibits anti–tubercular activity, with MICs of 132 μM and 264 μM for M. tuberculosis wild type (H37Rv) and clinical mutant strains (IC1 and IC2) .
    Benzothiohydrazide
  • HY-163110
    NNRT-IN-2

    		HIV Reverse Transcriptase Infection
    NNRT-IN-2 (compound 7w) is an orally available non-nucleoside reverse transcriptase inhibitor (NNRTI) with broad inhibitory effects on wild-type HIV-1 and mutant strains. NNRT-IN-2 inhibits HIV-1 reverse transcriptase with an EC50 of 22 nM. NNRT-IN-2 is insensitive to CYP and hERG and has good safety and pharmacokinetic characteristics .
    NNRT-IN-2
  • HY-174417
    NNRT-IN-10

    		Reverse Transcriptase HIV Potassium Channel Cytochrome P450 Infection
    NNRT-IN-10 is a potent, selective and orally active non-nucleoside HIV-1 reverse transcriptase (NNRTI) inhibitor with with an EC50 values ranging from 1.16 to 18.3 nM for HIV and its mutant strains. NNRT-IN-10 exhibits good pharmacokinetic properties and favorable safety profiles. NNRT-IN-10 can be used for the study of AIDS, caused by HIV-1 .
    NNRT-IN-10
  • HY-17040R
    Darunavir (Standard)

    TMC114 (Standard); UIC-94017 (Standard)

    		 HIV HIV Protease Reference Standards Infection Inflammation/Immunology
    Darunavir (Standard) is the analytical standard of Darunavir. This product is intended for research and analytical applications. Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity .
    Darunavir (Standard)
  • HY-175667
    NNRT-IN-12

    		HIV Reverse Transcriptase Infection
    NNRT-IN-12 (compound 19) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor with an IC50 value of 0.107 μM for WT HIV-1 RT. NNRT-IN-12 shows anti-HIV-1 activity with EC50 value of 14.1, 5.03, 7.64, 27.1 nM for L100I, K103N, Y181C, Y188L mutant HIV-1 strains, respectively. NNRT-IN-12 shows cytotoxicity .
    NNRT-IN-12
  • HY-19932
    MK-2748

    		HCV Protease HCV Infection
    MK-2748 is a hepatitis C virus (HCV) NS3/4a protease inhibitor. MK-2748 exhibits broad-spectrum and potent antiviral activity, with nanomolar-level activity against all genotypes (gt1a-gt6) (IC₅₀ < 0.115 nM), showing only slightly weaker activity against gt3a (1.212 nM), and maintaining high inhibitory activity against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 can be used in the research of HCV infection .
    MK-2748
  • HY-155114
    HIV-1 inhibitor-59

    		HIV Infection
    HIV-1 inhibitor-59 (Compound I-5b) is a HIV-1 inhibitor, with EC50s of 5.62-171 nM against the wild-type (WT) and mutant HIV-1 strains. HIV-1 inhibitor-59 has moderate RT enzyme inhibitory activity (IC50: 0.094-12.0 μM) .
    HIV-1 inhibitor-59
  • HY-116528
    GCA-186

    		HIV Infection
    GCA-186 is a potent anti-HIV-1 agent. GCA-186 is highly active against both wild type and mutated HIV-1 strains with EC50s of 1, 180, 1, and 40 nM for IIIB, IIIB-R(Y181C), NL4-3 and NL4-3K103N of HIV-1 strains, respectively .
    GCA-186
  • HY-N14782
    10-Decarbomethoxyaclacinomycin A

    		Antibiotic Bacterial Infection Cancer
    10-Decarbomethoxyaclacinomycin A is an anthracycline antibiotic can be produced by Streptomyces galilaeus MA144-Mlt mutant strain KE303. 10-Decarbomethoxyaclacinomycin A has antibacterial activities .
    10-Decarbomethoxyaclacinomycin A
  • HY-151938
    Reverse transcriptase-IN-3

    		HIV Infection
    Reverse transcriptase-IN-3 is a pyrimidine-5-carboxamide derivative, acts as an inhibitor of HIV-1. Reverse transcriptase-IN-3 shows potent activity against the HIV-1 wild-type and mutant strains .
    Reverse transcriptase-IN-3
  • HY-175491
    HIV-1-IN-85

    		HIV Reverse Transcriptase Infection
    HIV-1-IN-85 is an orally active HIV-1 inhibitor (IC50 = 72 nM). HIV-1-IN-85 exhibits strong inhibitory activity against wild-type (WT) HIV-1 and NNRTI-resistant single mutant strains (L100I, K103N, Y181C, Y188L, E138K) and moderate efficacy against double mutant strains (F227L+V106A, RES056). HIV-1-IN-85 shows good in vivo safety in ICR mice. HIV-1-IN-85 can be used for the study of HIV-1 infection .
    HIV-1-IN-85
  • HY-160678
    InhA-IN-7

    		Bacterial Infection
    InhA-IN-7 (Compound 11) is a Triclocan (HY-B1119) derivative with inhibitory activity towards enoyl-acyl carrier protein reductase (InhA) with an IC50 of 96 nM. InhA-IN-7 inhibits proliferations of Mycobacterium tuberculosis wildtype and mutant strains with MICs ranging from 19 to 75 μM .
    InhA-IN-7
  • HY-14780
    Viquidacin

    NXL 101

    		 Antibiotic Topoisomerase DNA/RNA Synthesis Bacterial Infection
    Viquidacin (NXL 101) is an antibiotic with inhibitory activity against topoisomerase IV and DNA gyrase. Viquidacin exhibits antibacterial activity against gram positive bacterial by inhibiting the supercoiling, decatenation and relaxation in strains Staphylococcus aureus and Escherichia coli in micromolar levels. Viquidacin inhibits S. aureus wildtype and mutants with MIC of 2-128 mg/L .
    Viquidacin
  • HY-114956
    AT-61

    		HBV Infection
    AT-61 is a non nucleoside HBV replication inhibitor. AT-61 prevents the capsid formation of pre genomic RNA, resulting in the production of empty capsids. AT-61 has the activity of drug-resistant mutant strains. AT-61 can be used for research on hepatitis B virus infection .
    AT-61
  • HY-149928
    NNRT-IN-1

    		HIV Infection
    NNRT-IN-1 (compound 8r) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor featuring significantly anti-resistance efficacy. NNRT-IN-1 inhibits the wild-type HIV-1 and five mutant strains with EC50s in the nanomolar range. NNRT-IN-1 displays favorable pharmacokinetic properties .
    NNRT-IN-1
  • HY-167642
    (Z)-Rilpivirine

    (Z)-R278474; (Z)-TMC278; (Z)-DB08864

    		 Drug Isomer HIV Reverse Transcriptase Infection
    (Z)-Rilpivirine ((Z)-R278474) is the (Z)-isomer of Rilpivirine (HY-10574). Rilpivirine is an effective and selective diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). It exhibits potent antiviral activity against both wild-type HIV (EC50 = 0.4 nM) and mutant strains (EC50 = 0.1-2.0 nM) .
    (Z)-Rilpivirine
  • HY-147841
    HIV-1 inhibitor-41

    		HIV Reverse Transcriptase Infection
    HIV-1 inhibitor-41 (Compound B23) is an orally active non-nucleoside HIV-1 reverse transcriptase inhibitor with EC50 values of 20.8 nM and 50 nM against HIV-1 WT and mutant E138K strain, respectively. HIV-1 inhibitor-41 shows low hERG, no apparent CYP enzymatic inhibition and no acute toxicity .
    HIV-1 inhibitor-41
  • HY-146746
    HIV-1 inhibitor-19

    		HIV Infection
    HIV-1 inhibitor-19 is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI). HIV-1 inhibitor-19 maintains its inhibitory activity against L100I, K103N and V106A/ F227L mutant strains with EC50s of 7.3 nM, 9.2 nM and 21.0 nM, respectively.
    HIV-1 inhibitor-19
  • HY-112585
    Darunavir-d9

    TMC114-d9; UIC-94017-d9

    		 HIV HIV Protease Infection Inflammation/Immunology
    Darunavir-d9 (TMC114-d9) is the deuterium labeled Darunavir. Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity .
    Darunavir-d9
  • HY-173277
    FtsZ-IN-13

    		Bacterial Infection
    FtsZ-IN-13 (Compound C11) is an inhibitor of temperature-sensitive mutant Z (FtsZ), with IC50 values of 47.97, 34 μM against FtsZSa and FtsZPa, respectively. FtsZ-IN-13 has a notable antimicrobial activity against S. aureus (minimum inhibitory concentration value of 2 μg/mL), cystic fibrosis S. aureus clinical isolates, and methicillin-resistant S. aureus (MRSA) strains. FtsZ-IN-13 can be used for antimicrobial resistance study .
    FtsZ-IN-13
  • HY-172408
    NNRT-IN-6

    		Reverse Transcriptase HIV Infection
    NNRT-IN-6 (Compound 13a) is the non-nucleoside reverse transcriptase inhibitor (NNRT) for HIV-1 reverse transcriptase (HIV-1 RT) with IC50 of 0.41 μM. NNRT-IN-6 inhibits HIV-1 wildtype and mutant strains L100I, K103N, Y181C, Y188L, E138K, F227L/V106A and RES056 with EC50 of 6.2-250 nM .
    NNRT-IN-6
  • HY-155059
    Antimycobacterial agent-6

    		Bacterial Infection
    Antimycobacterial agent-6 (compound 25) is a potent inhibitor of Mycobacterium tuberculosis (Mtb)，targeting to both wild-type and fluoroquinolone-resistant Mtb strains. Antimycobacterial agent-6 inhibits Mtb DprE1-C387S mutant with MIC90s of 0.9 μM (H37Rv)，0.9 μM (MoxR)，0.5 μM (DprE1-P116S)，respectively .
    Antimycobacterial agent-6
  • HY-162720
    NNRT-IN-4

    		HIV Potassium Channel Reverse Transcriptase Infection
    NNRT-IN-4 (Compound 10p) is an inhibitor for non-nucleoside reverse transcriptase (NNRT) with an IC50 of 0.713 µM for HIV-1 RT. NNRT-IN-4 exhibits antiviral efficacy, inhibits HIV-1 wildtype and mutant strains with EC50 of 6-63 nM. NNRT-IN-4 exhibits a slight inhibitory activities against hERG (IC50=25.9 µM) and CYP enzymes (IC50>50 µM). NNRT-IN-4 exhibits good tolerability and safety in mice (2 g/kg) .
    NNRT-IN-4
  • HY-178031
    HIV-1-IN-87

    		HIV Reverse Transcriptase Infection
    HIV-1-IN-87 (Compound 11x) is a dual-site HIV-1 inhibitor targeting the non-nucleoside reverse transcriptase inhibitor binding pocket (NNIBP) and its adjacent site (NNIAS). HIV-1-IN-87 has potent antiviral activities against wild-type and mutant strains (such as L100I, K103N and Y181C) (EC50: 4.1-150 nM). HIV-1-IN-87 can be used for HIV-1 infections like acquired immune deficiency syndrome (AIDS) research .
    HIV-1-IN-87
  • HY-152233
    Reverse transcriptase-IN-4

    		HIV Infection
    Reverse transcriptase-IN-4 (compound F10) is a potent and selective non-nucleoside reverse transcriptase (NNRT) inhibitor with an EC50 value of 0.053 μM for wild-type HIV-1 and an EC50 value of 0.26 μM for HIV-1 mutant E138K . Reverse transcriptase-IN-4 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Reverse transcriptase-IN-4
  • HY-169920
    HIV-1 inhibitor-79

    		HIV Reverse Transcriptase Infection
    HIV-1 inhibitor-79 (Compound 3k) is an HIV inhibitor that exhibits significant inhibitory activity against HIV-1 and its common mutant strains (with IC50 values of 1.9, 1.9, 8.7, and 11 nM against HIV-1, K103, L100I, and E138K, respectively), and has low cytotoxicity and a high selectivity index (CC50 = 21.95 μM, SI = 11478). Additionally, HIV-1 inhibitor-79 also shows antiviral activity against HIV-2, with an EC50 value of 6.14 μM, and significantly inhibits the activity of HIV-1 reverse transcriptase (IC50 = 25 nM) .
    HIV-1 inhibitor-79
  • HY-155046
    FGFR4-IN-14

    		FGFR Cancer
    FGFR4-IN-14 (Compound 27i) is a FGFR4 inhibitor (IC50: 2.4 nM. FGFR4-IN-14 inhibits the proliferation of V550L and N535K mutant strains, with IC50s of 21 nM, 2.5 nM, 171 nM against huh7, BaF3/ETV6-FGFR4-V550L and BaF3/ETV6-FGFR4-N535K cells respectively. FGFR4-IN-14 has potent antitumor efficacy in the Huh7 xenograft model. FGFR4-IN-14 can be used for research of hepatocellular carcinoma (HCC) .
    FGFR4-IN-14
  • HY-146019A
    HIV-1 inhibitor-25

    		HIV Infection
    HIV-1 inhibitor-25 (compound R-12a) is a highly potent HIV-1 reverse transcriptase, with an IC50 value of 0.1061 μM. HIV-1 inhibitor-25 has high antiretroviral activity against WT HIV-1 with an EC50 of 13.6 nM, and exhibits relatively low cytotoxicity with a CC50 of 33.13 μM in MT-4 cells. HIV-1 inhibitor-25 also has inhibitory activity against HIV-1 mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L+V106A) with EC50 of 0.1961 ~ 5.8136 μM. HIV-1 inhibitor-25 can be used for researching AIDS .
    HIV-1 inhibitor-25
  • HY-181090
    HIV-1-IN-92

    		HIV Infection
    HIV-1-IN-92 is a non-nucleoside inhibitor of HIV-1 reverse transcriptase with an IC50 of 0.11 μM against HIV-1 reverse transcriptase. HIV-1-IN-92 exhibits activity against both wild-type HIV-1 IIIB and mutant HIV-1 strains. HIV-1-IN-92 can be used in research related to acquired immunodeficiency syndrome (AIDS) .
    HIV-1-IN-92
  • HY-183551
    Antitubercular agent-59

    		Infection
    Antitubercular agent-59 is an orally active antitubercular agent with an IC50 of 51 nM against Mycobacterium tuberculosis H37Rv. Antitubercular agent-59 inhibits growth of Bedaquiline (HY-14881)-resistant Rv0678G12C mutant strains. Antitubercular agent-59 exerts bactericidal activity in chronic tuberculosis mouse models with 1-Aminobenzotriazole (HY-103389) coadministration .
    Antitubercular agent-59
  • HY-108029
    Deldeprevir sodium

    ACH-2684 sodium; Neceprevir sodium

    		 HCV HCV Protease Infection
    Deldeprevir (ACH-2684; Neceprevir) sodium is a HCV NS3/4A protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b HCV, including mutant strains resistant to other NS3 protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C .
    Deldeprevir sodium
  • HY-180149
    PRP020

    		ATP Synthase Bacterial Infection
    PRP020 is a potent and specific inhibitor of mycobacterial ATP synthase. PRP020 does not inhibit acidification driven by succinate. PRP020 exihibits MIC95 against M. tuberculosis of 2 μM, and it remains active against most drug-resistant mutant strains. PRP020 is highly safe and can be used in anti-tuberculosis research .
    PRP020
  • HY-115516
    BI-1388

    		HCV HCV Protease Ras Infection
    BI-1388 is a macrocyclic acylsulfonamide-based HCV NS3-4A protease inhibitor. BI-1388 inhibits clinically relevant drug-resistant mutant strains (KRAS D168V gt 1b and KRAS R155K gt 1a) and exhibits high liver distribution. BI-1388 is applicable for the research of HCV infection .
    BI-1388
  • HY-181713
    Antibiofilm agent-19

    		Bacterial G-quadruplex Infection
    Antibiofilm agent-19 is an antibiofilm agent with iron-chelating activity. Antibiofilm agent-19 potently inhibits biofilm formation by wild-type PAO1 and the hyper-biofilm mutant strain PAO1-ΔwspF. Antibiofilm agent-19 promotes the formation of c-di-GMP G-quadruplexes and disrupts iron acquisition systems. It can be used in studies on antibacterial adjuvants .
    Antibiofilm agent-19
  • HY-179437
    anti-HIV agent 1

    		HIV Infection
    anti-HIV agent 1 (compound 10i) is a potent antiviral agent with anti-HIV activity (IC50 = 10.6 nM). anti-HIV agent 1 exhibits moderate to no inhibitory activity against RT mutant strains, but maintains their activity against wild-type viruses. anti-HIV agent 1 strongly shows dual inhibition of the viral attachment and reverse transcriptase phases of the viral life cycle. anti-HIV agent 1 can be used for HIV infection research .
    anti-HIV agent 1
  • HY-181920
    RPG-01-132

    		PROTACs Dengue Virus Infection
    RPG-01-132 is a DENV capsid protein PROTAC degrader, with a DC50 of 2.4 μM. RPG-01-132 blocks viral assembly, eliminates viral particles, and interferes with the non-structural functions of capsid protein. RPG-01-132 exhibits significant antiviral activity against all four DENV serotypes and the ST148 (HY-121663)-resistant DENV2 mutant strain. RPG-01-132 is applicable to research related to dengue virus infection .
    RPG-01-132
  • HY-D3192
    CDy11

    		Fluorescent Dye Bacterial Amyloid-β Infection
    CDy11 is a fluorescent probe and amyloid-binding dye (λex=590 nm; λem=612 nm), with a Ka of 29 μM for Pseudomonas aeruginosa Fap. CDy11 specifically recognizes amyloid fibrils in bacterial biofilms and exhibits significantly enhanced fluorescence upon binding to the target. CDy11 shows no staining effect on amyloid-deficient mutant strains, planktonic cells or protein monomers. CDy11 supports in vivo imaging of Pseudomonas aeruginosa biofilms in mouse implant and corneal infection models. CDy11 is widely used in studies of Staphylococcus aureus biofilm infections, dental caries, and Pseudomonas aeruginosa-associated implant and corneal infections .
    CDy11

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: